Cell and gene therapies at the forefront of innovative medical care: Implications for South Africa by Pepper, M S et al.
20       January 2019, Vol. 109, No. 1
IN PRACTICE
Altering the human genome for therapeutic purposes is now a 
reality. Several forms of change are possible, but essentially they 
involve the addition, removal or alteration of DNA. Changes can 
be effected in various ways such as introducing DNA sequences 
into cells using viral vectors or using gene editing techniques. From 
an ethical perspective, gene editing is globally acceptable when 
performed on somatic cells (i.e. cells of the body excluding gametes – 
ova and sperm). Gene editing of gametes in humans, particularly for 
purposes of enhancement, is not condoned.
CAR T-cells
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is an 
effective new therapy for patients with aggressive B-cell malignancies 
including leukaemia and lymphoma. It genetically engineers T-cells 
to express a synthetic antigen receptor (i.e. the CAR), consisting 
of an extracellular antigen-recognising receptor (targeting CD19 
on B-cells in this therapeutic application) coupled to intracellular 
signalling domains that allow T-cell activation following recognition 
of the antigen. The therapy produces a redirected, effector T-cell anti-
tumour immune response in a major histocompatibility complex-
independent manner. Although CD19 is expressed on all B-cells, 
malignant and non-malignant, eradication of normal B-cells seems 
at this time to be well tolerated, and a recovery in non-malignant 
polyclonal B-cell expansion has been shown in patients with complete 
response to CD19 CAR T-cell therapy.[1,2]
Two CAR T-cell therapies (both targeting CD19, Table 1) were 
approved by the US Food and Drug Administration (FDA) in 
2017. The first, tisagenlecleucel, is indicated for relapsed/refractory 
(R/R) B-cell acute lymphoblastic leukaemia in paediatric and 
young patients (<25 years of age). In the pivotal clinical trial with 
75  participants (followed up to date), a complete remission rate of 
81% was reported. [3] This response rate is impressive considering that 
the participants had failed on two or more prior therapies, including 
allogeneic haematopoietic stem cell transplantation.
The second therapy, axicabtagene ciloleucel, is indicated for 
R/R B-cell lymphoma in adults. The pivotal clinical trial with 101 
participants reported a complete response rate of 54%.[4] This 
response is a notable improvement over the outcome of the prior 
standard of care, namely high-dose chemotherapy and autologous 
haematopoietic stem-cell transplantation, where overall response 
rates of <30% and a median overall survival of 6 months are generally 
observed.[5]
The European Commission and the National Institute for Health 
and Care Excellence (NICE) in the UK have recently also approved 
the use of both CAR T-cell therapies.[6] Initially, NICE stated that one 
of the treatments was too expensive to be eligible for coverage by the 
National Health Service; however, this decision was reversed once a 
way was found to reduce cost.[7]
Although these CAR T-cell therapies are approved for different 
indications and populations (Table 1), their functionality or mode 
of action is virtually identical: both target and kill CD19-expressing 
B-cells. Subtle differences do, however, exist in the architecture of 
the CAR (transmembrane and co-stimulatory domains), which may 
differentiate the rate of tumour killing and persistence of the CAR 
T-cells.[8] The risk of adverse events and even mortality related to 
neurotoxicity and a systemic immune response (cytokine release 
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syndrome) that is associated with CAR T-cell therapies[9] precludes 
interchangeability. This means that extrapolation of the CAR T-cell 
therapies to other patient populations, particularly children, when 
they have only been tested in adults,[10] should not be considered 
lightly. Safety of patients is the priority, followed by efficacy.
Accessibility and socioeconomic status
Often questioned is whether technological advances such as novel 
immunotherapies, gene therapy and genome editing are relevant to 
low- and middle-income countries (LMICs), given more pressing 
priorities such as delivery of basic healthcare services, education, and 
food and water security. Is it ethically justifiable for LMICs to support 
use of advanced technologies in the face of challenges in meeting the 
basic needs of the general population?
Distributive justice concerns the socially just allocation of goods 
in a society. Although reflecting a noble principle, it is problematic to 
enforce in resource-strapped settings. A simple egalitarian approach 
to distributive justice may, however, insist on meeting basic needs 
first, and it may be justifiable to allocate some resources to all 
populations who need healthcare. However, resource constraints 
require careful rationing decisions, often based on finding the most 
cost-effective treatments for commonly occurring diseases.
Antiretroviral therapy (ART) for HIV in South Africa (SA) 
provides a pertinent illustration. The principles of health economics 
lead to the view that it makes sense from both a clinical and an 
economic perspective to provide ART, because everyone stands 
to benefit. In practical terms, gene therapy for HIV leading to a 
‘cure’ would be possible and sensible, if the once-off cost of such 
gene therapy were less than the lifetime cost of HIV treatment, 
the anticipated medical complications and costs to society more 
broadly. Currently, the cost of gene therapy in SA would far 
outweigh the cost of lifetime ART for HIV, although the cost of 
anticipated medical complications and the costs to society are more 
difficult to define. Nonetheless, by analogy, the use of CAR T-cell 
therapies in SA is not currently sensible from a health economics 
perspective, since the infrastructure, equipment and manufacturing 
costs are likely to be prohibitive. In the USA, the costs for the FDA-
approved CAR T-cell therapies are USD475 000 and USD373 000 
for tisagenlecleucel and axicabtagene ciloleucel, respectively.[11] In 
general, lower costs are expected for provision of these treatments 
in Europe and the UK.[7,12] Cost reductions are likely to occur in 
the future as these technologies are refined and adapted to local 
settings. One should also bear in mind that economies of scale are 
likely to result in significant cost reductions.
According to the World Bank, SA has the highest Gini coefficient 
globally, which reflects large inequalities in individual/household 
incomes. This inequality is clearly visible in the healthcare sector, 
where more than 50% of total annual health expenditure in the 
country is in the private health sector (<20% of the population), 
while less than 50% is in the public health sector (which serves 
>80% of the population). Several high-end (expensive) technologies 
are available in the private sector but not in the public sector, which 
is challenged by budget constraints. It is therefore possible that 
innovative medicines such as CAR T-cell therapies may enter the SA 
market initially through the private sector. Although it is regrettable 
that public sector patients may not benefit initially, being able 
to demonstrate the efficacy of these innovative medicines in SA 
patients may persuade the funders of public healthcare to allocate 
resources for the application of these new medicines, albeit at a 
significantly lower cost.
This state of affairs raises the question whether SA should refrain 
from participation and simply be a bystander in the development of 
rapidly evolving and highly efficacious, albeit costly, new medicines. 
Arguably, the answer is a resounding negative. To refrain from 
participation in relevant research and innovative medical practice 
that, in time, may benefit all South Africans, merely because of 
current resource constraints, is not sensible or reasonable.
Regulatory oversight
Although manufacture of CAR T-cell and other immune and gene 
therapies is technologically demanding and resource intensive, it will 
be possible to overcome these limitations in SA once facilities are 
constructed and personnel are appropriately trained. The healthcare 
regulatory system, on the other hand, is markedly underdeveloped 
and is likely to be challenged by the ethical, legal and social 
requirements implicated by these new therapies. The challenges must 
be addressed as soon as possible using guidance and lessons learnt 
from the USA and EU. It may be noted that on 11 June 2018, the US 
FDA published detailed and comprehensive draft guidance for the 
development, review and approval of gene therapies, which addresses 
issues related to manufacturing, testing and long-term follow-up. 
In addition, specific guidance was provided for gene therapy for 
haemophilia, retinal disorders and rare diseases.[13]
Conclusions
It is critical that SA’s diverse populations are involved in research on 
these new therapies to ensure that they will be safe and effective for 
local use. Time and effort should be devoted as a matter of urgency to 
finding novel and innovative ways to introduce innovative therapies 
such as those described here into the healthcare sector in SA while 
recognising the diverse needs in our society. This will allow all 
deserving patients, irrespective of socioeconomic status, to benefit 
from these new developments and not simply to be bystanders in a 
rapidly evolving field.
Table 1. Approved CAR T-cell therapies
Tisagenlecleucel (Kymriah; Novartis) Axicabtagene ciloleucel (Yescarta; Gilead/Kite Pharma)
Description                                       CD19-directed genetically modified autologous T-cell therapy
Indication Paediatric and young (<25 years) patients with B-cell 
precursor ALL that is refractory or in second or later 
relapse
Adult patients with relapsed or refractory large B-cell 
lymphoma after two or more lines of systemic therapy. 
Includes DLBCL not otherwise specified, primary mediastinal 
large B-cell lymphoma, high grade B-cell lymphoma, and 
DLBCL arising from follicular lymphoma
Dosage 0.2 - 5.0 × 106 CAR T-cells/kg (for patients <50 kg)
0.1 - 2.5 × 108 total CAR T-cells (for patients >50 kg)
2 × 106 CAR T-cells/kg (maximum 2 × 108)
Gene delivery Lentiviral vector Gamma-retroviral vector
CAR = chimeric antigen receptor; ALL = acute lymphoblastic leukaemia; DLBCL = diffuse large B-cell lymphoma.
22       January 2019, Vol. 109, No. 1
IN PRACTICE
Declaration. None.
Acknowledgements. None.
Author contributions. MSP: initial manuscript conception, initial 
drafting and subsequent editing; MA: conceptual refinement and 
manuscript editing; AP: conceptual refinement and manuscript editing; 
WvS: conceptual refinement and manuscript editing; RJG: conceptual 
refinement and manuscript editing.
Funding. Work in MSP’s group is funded by the South African Medical 
Research Council (University Flagship and Extramural Unit awards).
Conflicts of interest. None
1. Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large B cell 
lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther 2017;25(10):2245-2253. 
https://doi.org/10.1016/j.ymthe.2017.07.004
2. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med 2018;379(1):64-73. https://doi.
org/10.1056/NEJMra1706169
3. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell 
lymphoblastic leukemia. N Engl J Med 2018;378(5):439-448. https://doi.org/10.1056/NEJMoa1709866
4. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large 
B-cell lymphoma. N Engl J Med 2017;377(26):2531-2544. https://doi.org/10.1056/NEJMoa1707447
5. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results 
from the International SCHOLAR-1 Study. Blood 2017;130(16):1800-1808. https://doi.org/10.1182/
blood-2017-03-769620
6. The Scientist. Two CAR T-cell therapies greenlighted in Europe. https://www.the-scientist.com/news-
opinion/two-car-t-cell-therapies-greenlighted-in-europe-64720 (accessed 20 November 2018).
7. Pharmaphorum. NHS to reimburse Gilead’s CAR-T in adults. https://pharmaphorum.com/news/nhs-
to-reimburse-gileads-car-t-in-adults/ (accessed 20 November 2018).
8. Tran E, Longo DL, Urba WJ. A milestone for CAR T cells. N Engl J Med 2017;377(26):2593-2596. 
https://doi.org/10.1056/NEJMe1714680
9. Le RQ, Li L, Yuan W, et al. FDA approval summary: Tocilizumab for treatment of chimeric 
antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 
2018;23(8):943-947. https://doi.org/10.1634/theoncologist.2018-0028
10. Pepper MS, Pope A, Kling S, Alessandrini M, van Staden W, Green RJ. Ethical considerations in the 
application of cell and gene therapies in children. S Afr Med J 2018;108(12):1027-1029. https://doi.
org/10.7196/SAMJ.2018.v108i12.13585
11. American Journal of Managed Care. Evidence-based Oncology. With approval of CAR T-cell therapy 
comes the next challenge: Payer coverage. 21 February 2018. https://www.ajmc.com/journals/
evidence-based-oncology/2018/february-2018/with-approval-of-car-tcell-therapy-comes-the-next-
challenge-payer-coverage (accessed 20 November 2018).
12. Savage P, Mahmoud S, Patel Y, et al. Cancer drugs: An international comparison of postlicensing price 
inflation. J Oncol Pract 2017;13(6):e538-e542. https://doi.org/10.1200/JOP.2016.014431
13. US Food and Drug Administration. Vaccines, Blood & Biologics. Cellular & Gene Therapy Guidances, 
July 2018. https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformati
on/Guidances/CellularandGeneTherapy/default.htm (accessed 20 November 2018).
Accepted 23 August 2018.
